PMID- 18376194
OWN - NLM
STAT- MEDLINE
DCOM- 20080421
LR  - 20080331
IS  - 0003-4932 (Print)
IS  - 0003-4932 (Linking)
VI  - 247
IP  - 3
DP  - 2008 Mar
TI  - Serum vascular endothelial growth factor C correlates with lymph node metastases 
      and high-risk tumor profiles in papillary thyroid carcinoma.
PG  - 483-9
LID - 10.1097/SLA.0b013e31815fa447 [doi]
AB  - OBJECTIVE: To evaluate the clinical relevance of serum vascular endothelial 
      growth factor (VEGF) and VEGF-C in papillary thyroid carcinoma (PTC). SUMMARY 
      BACKGROUND DATA: VEGF is a potent angiogenic factor promoting tumor angioinvasion 
      and distant metastases, whereas VEGF-C enhances nodal metastases because of its 
      lymphangiogenic effect. Although both tissues VEGF and VEGF-C have been shown to 
      contribute to tumor metastases in PTC, the clinical relevance of serum VEGF 
      (sVEGF) and sVEGF-C remains unknown. METHODS: Preoperative serum samples 
      collected from 85 primary PTC patients and 44 control subjects with benign 
      thyroid diseases were measured for sVEGF and sVEGF-C levels. Potential 
      correlations between their serum levels and clinicopathologic features as well as 
      the commonly adopted risk group stratification profiles of the tumors were 
      analyzed. RESULTS: Preoperative sVEGF and sVEGF-C levels of PTC patients were 
      significantly higher compared with those of control subjects (P = 0.001 and P < 
      0.001, respectively). sVEGF-C level was significantly elevated in older patients, 
      those with extrathyroidal invasion and with lymph node metastases whereas sVEGF 
      level was significantly increased in multifocal tumors. sVEGF-C, but not sVEGF, 
      correlated significantly with high risk tumors in all commonly adopted risk group 
      stratification profiles. An elevated preoperative sVEGF-C level of >7200 pg/mL 
      was shown to be the only independent risk factor for nodal metastases. sVEGF-C 
      levels declined significantly at 3 months after thyroidectomy in PTC but not 
      control patients. CONCLUSIONS: sVEGF-C levels in PTC patients correlated 
      significantly with the presence of nodal metastases and advanced tumor stages. 
      Its clinical relevance needs further evaluation.
FAU - Yu, Xiao-Min
AU  - Yu XM
AD  - Department of Surgery, The University of Hong Kong, Queen Mary Hospital, 
      Pokfulam, Hong Kong.
FAU - Lo, Chung-Yau
AU  - Lo CY
FAU - Lam, Alfred King-Yin
AU  - Lam AK
FAU - Leung, Pauline
AU  - Leung P
FAU - Luk, John M
AU  - Luk JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factor C)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Papillary/*blood/surgery
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Lymphatic Metastasis/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Thyroid Diseases/blood
MH  - Thyroid Neoplasms/*blood/surgery
MH  - Thyroidectomy
MH  - Vascular Endothelial Growth Factor A/blood
MH  - Vascular Endothelial Growth Factor C/*blood
EDAT- 2008/04/01 09:00
MHDA- 2008/04/22 09:00
CRDT- 2008/04/01 09:00
PHST- 2008/04/01 09:00 [pubmed]
PHST- 2008/04/22 09:00 [medline]
PHST- 2008/04/01 09:00 [entrez]
AID - 00000658-200803000-00014 [pii]
AID - 10.1097/SLA.0b013e31815fa447 [doi]
PST - ppublish
SO  - Ann Surg. 2008 Mar;247(3):483-9. doi: 10.1097/SLA.0b013e31815fa447.